Related Experiment Videos
Innominate artery endarterectomy. A 16-year experience
Insights
Transsternal endarterectomy effectively treats innominate artery atherosclerosis, with most patients remaining asymptomatic long-term. This surgical approach offers durable arterial patency and symptom relief for cerebrovascular disease patients.
Area of Science:
- Vascular Surgery
- Cerebrovascular Disease
- Atherosclerosis Research
Background:
- Symptomatic atherosclerosis of the innominate artery poses a risk for transient ischemic attacks and stroke.
- Surgical intervention is considered for severe cases, but long-term outcomes require evaluation.
Purpose of the Study:
- To assess the efficacy and long-term outcomes of transsternal endarterectomy for symptomatic innominate artery atherosclerosis.
- To evaluate patient survival, symptom recurrence, and arterial patency after the procedure.
Main Methods:
- Retrospective analysis of 37 patients undergoing transsternal endarterectomy for innominate artery atherosclerosis.
- Data collection on mortality, postoperative symptoms, and arterial patency through long-term follow-up.
Main Results:
- A 6% mortality rate was observed in 34 patients who underwent the procedure.
- 30 of 32 survivors (93.75%) were asymptomatic at an average follow-up of 6.1 years.
- Complete cessation of transient ischemic attacks occurred in 6 patients with ulcerated, nonstenotic lesions.
- Normal arterial patency was maintained for up to 16 years postoperatively.
Conclusions:
- Transsternal endarterectomy is a viable and effective surgical option for symptomatic innominate artery atherosclerosis.
- The procedure offers significant long-term benefits, including symptom resolution and durable arterial patency.
- Endarterectomy can successfully manage complex atherosclerotic lesions, improving patient outcomes in cerebrovascular disease.
Abstract:
Transsternal endarterectomy was performed in 34 of 37 patients with symptomatic atherosclerosis of the innominate artery, with a mortality of 6%. Thirty of the 32 survivors are asymptomatic at an average of 6.1 years postoperatively. Six of these patients who had ulcerated, nonstenotic atherosclerotic lesions have had complete cessation of preoperative transient ischemic attacks. Normal arterial patency has been maintained for follow-up periods varying from seven months to 16 years.